Scholar Rock to Present at 2016 Wedbush PacGrow Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Scholar Rock, a biotechnology company focused on discovering and developing drugs that selectively target supracellular activation of growth factors in the disease microenvironment, today announced that Nagesh Mahanthappa, PhD, President and Chief Executive Officer of Scholar Rock, will present a company overview at the 2016 Wedbush PacGrow Healthcare Conference on Wednesday, August 17, 2016, at 3:05 p.m. EDT in New York, NY.

About Scholar Rock

Scholar Rock is a biotechnology company focused on discovering and developing a novel class of biologic therapies that target supracellular activation of growth factors in the disease microenvironment. The Company’s initial proprietary and partnered drug discovery programs target specific growth factors which are present in the microenvironments of significant diseases, including fibrosis, musculoskeletal diseases, immuno-oncology and autoimmune diseases. Scholar Rock was founded upon discoveries made by its scientific founders, Professors Timothy Springer, PhD, and Leonard Zon, MD, of Boston Children's Hospital and Harvard Medical School, related to the molecular mechanisms of supracellular activation. The company is backed by leading investors, including Polaris Partners, Timothy Springer, ARCH Venture Partners, Fidelity Investments, EcoR1 Capital, The Kraft Group, and Cormorant Asset Management.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160811005233/en/

Investor Contact:
Stern Investor Relations, Inc.
Stephanie Ascher, 212-362-1200
[email protected]
or
Media Contact:
The Yates Network
Kathryn Morris, 845-635-9828
[email protected]

Source: Scholar Rock

You May Also Be Interested In

• Paysafe Launches Video Gaming Arena to Connect Publishers with Millions of Gamers
• Aktietilbagekøb i SJF Bank A/S – transaktioner i uge 34
• ImmunoForge Selected for the Ministry of SMEs and Startups' 'Global TIPS R&D' Program… "Expansion of the LMT Platform"